Cancers are diseases described by the irregular spread of cells that have developed invasive features, enabling them to invade adjacent tissues. The specific diagnosis and effective management of oncological treatments depend on the timely detection of circulating tumor cells (CTCs) in a patient’s bloodstream. One of the most promising approaches to CTC separation from blood fractions involves the dielectrophoresis (DEP) technique. This research presents a new DEP-based bionic system designed for MDA-MB-231 breast cancer cell isolation from white blood cell (WBC) subtypes with a viable approach to cell viability. This work leverages the principle that every cell type possesses a unique dielectric fingerprint. This dielectrophoresis microfluidic device is designed to act as a scanner, reading these fingerprints to achieve a continuous, label-free separation of cancer cells from blood components with a high efficiency. In the proposed system that consists of three different stages, the first stage allows for separating B-lymphocytes and Monocytes fromb Granulocytes and MDA-MB-231 cells. The separation of B-lymphocytes from Monocytes occurs in the second step, while the last step concerns the separation of Granulocytes and MDA-MB-231 cells. In the analysis, x-y graphs of the electric potentials, velocity fields, pressure distributions, and cellular DEP forces applied to the cells, as well as the resulting particle paths, are provided. The model predicts that the system operates with a separation efficiency of nearly 92%. This work focuses on an investigation of the impact of electrode potentials, the velocity of cells, the number of electrodes, the width of the channel, and the output angles on enhancing the separation efficiency of particles.
